Suprane

To be administered only by those experienced in general anesthesia. Have intubation, artificial ventilation, oxygen and circulatory resuscitation available. Risk of malignant hyperthermia; discontinue all triggering agents if suspected (eg, volatile anesthetic agents, succinylcholine). Not appproved for maintenance of anesthesia in non-intubated children (due to increased incidence of respiratory adverse reactions). Children (esp. ≤6yrs) under maintenance anesthesia via laryngeal mask airway (LMA) are at increased risk of respiratory events (esp. with removal of LMA under deep anesthesia); monitor closely. Increased risk of airway narrowing and resistance in children with asthma or history of recent upper airway infection; monitor closely. Risk of sensitivity hepatitis with previous sensitization to halogenated anesthetics. Hepatic disease; consider alternatives to halogenated anesthetics. Do not use as sole agent for induction in coronary artery disease or where increases in HR or BP are undesirable. Intracranial space occupying lesions; increased cerebrospinal fluid pressure (see full labeling). Latent or overt neuromuscular disease (eg, Duchenne muscular dystrophy). Pediatric neurotoxicity risk with repeated or prolonged use. Susceptibility to QT prolongation (eg, congenital long QT syndrome, concomitant QT-prolonging drugs); monitor cardiac rhythm. Elderly (adjust dose). Labor & delivery. Pregnancy. Nursing mothers.